Table 1.

Torsade de pointes potential and post-marketing adverse events associated with possible COVID-19-repurposed pharmacotherapies

	CredibleMeds classification	VT/VF/TdP/LQTS in FAERS	Cardiac arrest in FAERS
Repurposed antimalarial agents
Chloroquine	Known risk	72	54
Hydroxychloroquine	Known risk	222	105
Repurposed antiviral agents
Lopinavir/ritonavir	Possible risk	27	48
Adjunct agents
Azithromycin	Known risk	396	251

Reproduced with permission from Giudicessi et al.⁵

COVID-19 = coronavirus disease 2019; FAERS = U.S. Food and Drug Administration Adverse Event Reporting System; LQTS = long-QT syndrome; TdP = torsade de pointes.